Fred Poordad F, et al. - In patients with chronic hepatitis C virus genotype 1a-infection without cirrhosis, researchers evaluated the safety and effectiveness of ombitasvir/paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) with low-dose ribavirin for 12 weeks in this open-label, multicenter, phase 3 study. The 105 patients enrolled had a sustained virologic response of 89.5% at post-treatment week 12. For patients in whom full-dose ribavirin could lower tolerability, OBV/PTV/r + DSV plus low-dose ribavirin appears a viable alternative, though its noninferiority to the weight-based ribavirin regimen was not established.